Community-Acquired Pneumonia

🩺What is Community-Acquired Pneumonia?

The CURB-65 score was developed by Lim et al. as part of the British Thoracic Society (BTS) collaborative study, published in Thorax in 2003. It was designed as a simplified and validated severity assessment tool for community-acquired pneumonia (CAP) that could be readily calculated at the bedside. The score is derived from the earlier CURB score and incorporates five binary variables, each contributing 1 point: new-onset confusion (C), blood urea nitrogen greater than 19 mg/dL or urea greater than 7 mmol/L (U), respiratory rate of 30 breaths per minute or greater (R), systolic blood pressure below 90 mmHg or diastolic blood pressure 60 mmHg or less (B), and age 65 years or older (65). The total score ranges from 0 to 5, and the score correlates with 30-day mortality in a stepwise fashion. The validation cohort included over 80,000 patients across multiple countries. The CURB-65 score is recommended by the British Thoracic Society and the National Institute for Health and Care Excellence (NICE) for severity assessment in CAP. A related score called CRB-65 excludes the urea measurement and is appropriate for primary care settings where laboratory testing is unavailable. CURB-65 is one of the most widely used pneumonia severity scores globally due to its simplicity and robust validation.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Community-Acquired Pneumonia:

• CURB-65 Score Calculator

  The CURB-65 score is a validated clinical prediction tool used to assess the severity of community-acquired pneumonia and guide decisions on whether to treat patients as outpatients or admit them to the hospital.

• PSI/PORT Score Calculator

  The Pneumonia Severity Index (PSI), also known as the PORT score, is a comprehensive clinical prediction tool for assessing mortality risk in community-acquired pneumonia. It assigns patients to one of five risk classes (I-V).

• DECAF Score — COPD Exacerbation Mortality

  The DECAF Score is a validated clinical prediction tool for estimating in-hospital mortality risk in patients admitted with acute exacerbation of COPD (AECOPD). It combines five easily assessed clinical parameters: Dyspnea (eMRCD score), Eosinopenia, Consolidation on chest X-ray, Acidemia, and atrial Fibrillation. The score helps clinicians stratify patients for appropriate level of care and guide treatment intensity.

🧬Diagnostic Logic & Scoring Breakdown

The CURB-65 score is calculated by summing 1 point for each of five binary clinical variables present at the time of initial assessment. The "C" criterion (confusion) is defined as new-onset disorientation to person, place, or time, or a Mental Test Score of 8 or less — this reflects acute brain dysfunction due to infection, hypoxia, or metabolic derangement. The "U" criterion (urea) is met when blood urea nitrogen exceeds 19 mg/dL (equivalent to serum urea > 7 mmol/L or approximately 40 mg/dL of urea); azotemia in pneumonia reflects dehydration, renal hypoperfusion, or underlying chronic kidney disease. The "R" criterion (respiratory rate) is met when the respiratory rate is 30 breaths per minute or greater; tachypnea is a sensitive marker of respiratory distress and impending respiratory failure. The "B" criterion (blood pressure) is met when systolic blood pressure is below 90 mmHg or diastolic blood pressure is 60 mmHg or less; hypotension in pneumonia indicates possible sepsis with vasodilation or hypovolemia. The "65" criterion (age) is met when the patient is 65 years or older; age is an independent risk factor for mortality in pneumonia due to immunosenescence and reduced physiologic reserve. The total score ranges from 0 to 5. The 30-day mortality rate shows a clear stepwise increase: 0.6-2.7% for score 0-1, 6.8% for score 2, 14-17.5% for score 3, and 27.8% for scores 4-5. The score is used to guide site-of-care decisions: scores of 0-1 are suitable for outpatient management, score 2 may require short-stay hospital observation, and scores of 3-5 generally require inpatient admission with consideration for ICU for scores 4-5.

📢Clinical Significance & Implications

The CURB-65 score is formally recommended by the British Thoracic Society (BTS) guidelines for the management of community-acquired pneumonia in adults (updated 2009) and by the National Institute for Health and Care Excellence (NICE) guideline NG195 (2019) for assessing pneumonia severity and guiding antibiotic prescribing. The score serves as the primary severity assessment tool in the UK National Health Service and is widely used internationally. In clinical practice, CURB-65 helps clinicians make evidence-based decisions about: (1) site of care — whether to manage as an outpatient, short-stay observation, or inpatient; (2) antibiotic choice — oral vs. intravenous therapy; and (3) level of monitoring. A score of 0-1 identifies low-risk patients who can be safely treated at home with oral antibiotics, potentially reducing unnecessary hospital admissions. A score of 2 identifies patients who may benefit from a short period of hospital observation. Scores of 3-5 identify high-risk patients requiring inpatient care, with scores of 4-5 warranting ICU assessment. The BTS guidelines also recommend the CRB-65 version (which omits the urea measurement) for use in primary care settings. Despite its widespread use, CURB-65 is less sensitive than the PSI/PORT score for identifying low-risk patients who can be safely treated as outpatients. Additionally, CURB-65 may underestimate severity in younger patients (who do not score for age) and does not account for important comorbidities, hypoxia, or social factors that may influence admission decisions. Therefore, CURB-65 should be used alongside clinical judgment rather than as a standalone decision tool.

💡 Clinical Assessment Scenario Example

An 80-year-old woman with no significant past medical history presents to the emergency department with a five-day history of productive cough, fever, and progressive dyspnea. Her family reports that over the past 24 hours she has become increasingly confused and disoriented. On examination, her temperature is 39.1°C, heart rate is 110 bpm, blood pressure is 100/60 mmHg, and respiratory rate is 32 breaths per minute with oxygen saturation of 87% on room air. Chest auscultation reveals coarse crackles over the right base. Chest X-ray confirms a right lower lobe consolidation. Laboratory results show white blood cell count 18,000/µL, BUN 25 mg/dL, creatinine 1.1 mg/dL, and serum glucose 110 mg/dL. CURB-65 assessment: confusion present (C = 1 point), BUN 25 > 19 mg/dL (U = 1 point), respiratory rate 32 ≥ 30 (R = 1 point), blood pressure 100/60 — systolic is 100, which is not below 90, and diastolic is 60, which equals 60 (B = 0 points), age 80 ≥ 65 (65 = 1 point). Total CURB-65 = 4 out of 5, indicating high severity with an expected 30-day mortality of approximately 27.8%. Management recommendations: immediate hospital admission, intravenous antibiotics (co-amoxiclav or ceftriaxone plus azithromycin per local guidelines), blood and sputum cultures, oxygen therapy to maintain SpO₂ ≥ 92%, close monitoring of respiratory status, and strong consideration for ICU-level care given her age, confusion, tachypnea, and elevated BUN. Daily reassessment of CURB-65 is warranted to track response to therapy.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Community-Acquired Pneumonia:

🔗Related Diseases & Conditions

These conditions are clinically associated with Community-Acquired Pneumonia through shared risk-scoring calculators and assessment tools:

• Sepsis
• Acute Respiratory Failure
• Pleural Effusion
• Chronic Obstructive Pulmonary Disease
• Atrial Fibrillation

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Using BUN instead of serum urea in mmol/L

  ✅ Correction: The "U" in CURB-65 refers to BUN > 19 mg/dL (which is equivalent to urea > 7 mmol/L or 40 mg/dL). Check your local lab units carefully.

• ❌ Mistake: Ignoring age in patients under 65 with severe pneumonia

  ✅ Correction: While age ≥ 65 gives 1 point, younger patients can still have severe pneumonia requiring admission. Use clinical judgment alongside the score.

• ❌ Mistake: Using CURB-65 for hospital-acquired pneumonia

  ✅ Correction: CURB-65 was validated for community-acquired pneumonia (CAP). Other scores (PSI/PORT, SMART-COP) may be more appropriate for hospital-acquired pneumonia.

• ❌ Mistake: Using CRB-65 when CURB-65 laboratory data is available

  ✅ Correction: CRB-65 is designed for settings without lab access. When BUN is available, always calculate CURB-65 for better prognostic accuracy.

• ❌ Mistake: Not considering hypoxia and oxygen saturation

  ✅ Correction: CURB-65 does not include oxygen saturation. A patient with low SpO₂ but low CURB-65 may still require admission for oxygen therapy. Always assess oxygenation separately.

• ❌ Mistake: Using PSI for immunocompromised patients

  ✅ Correction: PSI was developed and validated for immunocompetent adults with CAP. It may underestimate severity in immunocompromised patients (HIV, transplant, chemotherapy).

• ❌ Mistake: Not subtracting 10 for female patients

  ✅ Correction: Female patients start with an age score 10 points lower than males (age minus 10). This accounts for lower baseline mortality in women.

• ❌ Mistake: Ignoring PSI in favor of clinical gestalt alone

  ✅ Correction: PSI is validated to outperform clinical judgment alone for determining safe outpatient management. Use PSI alongside clinical assessment.

• ❌ Mistake: Counting neoplastic disease incorrectly

  ✅ Correction: Neoplastic disease in PSI refers to active cancer, not history of cured cancer. Excludes non-melanoma skin cancer. Metastatic disease should be counted.

• ❌ Mistake: Using PSI without assessing social and functional factors

  ✅ Correction: PSI provides mortality risk but does not account for social support, functional status, or ability to take oral medications. A low-risk patient with poor home support may still require admission.

• ❌ Mistake: Using DECAF for stable COPD risk assessment

  ✅ Correction: DECAF is specifically validated for in-hospital mortality prediction in AECOPD. It should not be used for stable COPD risk stratification or for predicting long-term outcomes.

• ❌ Mistake: Using venous pH instead of arterial pH

  ✅ Correction: DECAF was validated using arterial blood gas pH. Venous pH may differ and has not been validated for this score. Use arterial pH when calculating DECAF.

• ❌ Mistake: Not including history of AF as a positive criterion

  ✅ Correction: DECAF includes known history of atrial fibrillation, not just current AF on ECG. Check patient's medical history for prior AF diagnosis.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Community-Acquired Pneumonia; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References